Five Prime Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Five Prime Therapeutics Inc (FPRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Five Prime Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Five Prime Therapeutics Inc | No | No | No | No |
| High-Confidence Competitors (72) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 62.50 % (5 of 8) | 62.50 % (5 of 8) | 50.00 % (4 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
FPRX Stock Performance relative to its Competitors
FPRX Stock Performance relative to High-Confidence Competitors
FPRX Stock Performance relative to Similar Growth & Profitability Competitors
Five Prime Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Five Prime Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Zevra Therapeutics Inc | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Viridian Therapeutics Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| G1 Therapeutics Inc | Company report | 85% |
| Adlai Nortye Ltd | Company report | 85% |
| ADAPTIN BIO, INC. | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Nutra Pharma Corp | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Cardiff Oncology Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Theriva Biologics inc | Company report | 85% |
| Puretech Health Plc | Company report | 85% |
| Camp4 Therapeutics Corporation | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Vor Biopharma Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Generation Bio Co | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Five Prime Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Five Prime Therapeutics Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.